NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RSLS

ReShape Lifesciences Inc

Jun 20 • 04:00PM ET

2.55

Dollar change -0.01
Percentage change -0.39	%

Healthcare • Medical Devices • USA • NASD

Peers: JNJ ISRG MDT SYK BSX ABT EW ZBH GMED HOLX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-210.70	Insider Own	0.00%	Shs Outstand	2.39M	Perf Week	-18.01%
Market Cap	6.08M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	2.39M	Perf Month	-56.93%
Enterprise Value	3.59M	PEG	-	EPS next Q	-	Inst Own	10.04%	Short Float	1.41%	Perf Quarter	-85.34%
Income	-3.46M	P/S	0.85	EPS this Y	-	Inst Trans	0.28%	Short Ratio	0.01	Perf Half Y	-97.72%
Sales	7.17M	P/B	0.28	EPS next Y	-	ROA	-47.07%	Short Interest	0.03M	Perf YTD	-97.71%
Book/sh	9.24	P/C	2.32	EPS next 5Y	-	ROE	-120.16%	52W High	414.99 -99.39%	Perf Year	-99.15%
Cash/sh	1.10	P/FCF	-	EPS past 3/5Y	90.62% 80.05%	ROIC	-278.38%	52W Low	2.23 14.35%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-16.19% 19.53%	Gross Margin	63.74%	Volatility	8.92% 19.58%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	0.50	EPS Y/Y TTM	93.58%	Oper. Margin	-87.75%	ATR (14)	1.06	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.91	Sales Y/Y TTM	-13.92%	Profit Margin	-48.26%	RSI (14)	36.80	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.53	EPS Q/Q	114.00%	SMA20	-33.29%	Beta	1.31	Target Price	1450.00
Payout	-	Debt/Eq	0.11	Sales Q/Q	-42.75%	SMA50	-61.76%	Rel Volume	0.10	Prev Close	2.56
Employees	18	LT Debt/Eq	0.01	Earnings	May 21 BMO	SMA200	-96.90%	Avg Volume	3.00M	Price	2.55
IPO	Oct 06, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	315,950	Change	-0.39%

Jun-12-25 08:25AM	ReShape Lifesciences Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets (GlobeNewswire) +35.81%
Jun-09-25 09:00AM	ReShape Lifesciences Announces Pricing of $2.6 Million Public Offering (GlobeNewswire) -37.80%
Jun-03-25 08:31AM	ReShape Lifesciences Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio (GlobeNewswire) +56.61%
May-21-25 08:31AM	ReShape Lifesciences Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -13.51%
May-07-25 08:38AM	ReShape Lifesciences announces 1-for-25 reverse stock split (Seeking Alpha) -20.54%
08:31AM	Loading…
May-02-25 08:31AM	ReShape Lifesciences Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium (GlobeNewswire) +23.89%
Apr-28-25 08:31AM	ReShape Lifesciences Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System (GlobeNewswire)
Apr-21-25 08:31AM	ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology (GlobeNewswire) +23.73%
Apr-10-25 05:54PM	ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript) (Seeking Alpha) +65.58% -18.53%
Apr-09-25 04:05PM	ReShape Lifesciences Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market (GlobeNewswire) -9.71%
Apr-07-25 04:05PM	ReShape Lifesciences Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.80% -12.53%
Mar-10-25 08:31AM	ReShape Lifesciences Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology (GlobeNewswire) -18.83%
Feb-25-25 08:31AM	ReShape Lifesciences Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band 2.0 FLEX (GlobeNewswire) -15.44%
Feb-15-25 11:17PM	ReShape Lifesciences Announces Pricing of Upsized $6.0 Million Public Offering (GlobeNewswire)
Feb-03-25 08:31AM	ReShape Lifesciences Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology (GlobeNewswire) -5.84%
08:31AM	Loading…
Jan-13-25 08:31AM	ReShape Lifesciences Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys (GlobeNewswire) +11.11%
Nov-14-24 04:05PM	ReShape Lifesciences Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.01%
Nov-12-24 04:05PM	ReShape Lifesciences to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update (GlobeNewswire) -5.30%
08:31AM	ReShape Lifesciences Receives Health Canada Approval for its Next-Generation Lap-Band 2.0 FLEX (GlobeNewswire)
Nov-11-24 08:31AM	ReShape Lifesciences Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation Technology (GlobeNewswire)
Sep-23-24 09:48AM	Upcoming Stock Splits This Week (September 23 to September 27) Stay Invested (TipRanks) +23.00%
Sep-19-24 08:31AM	ReShape Lifesciences Announces 1-for-58 Reverse Stock Split (GlobeNewswire) -20.18%
Aug-14-24 04:05PM	ReShape Lifesciences Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-13-24 08:31AM	ReShape Lifesciences to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update (GlobeNewswire)
Jul-09-24 12:13PM	Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol HIND (GlobeNewswire) +6.51%
08:31AM	ReShape Lifesciences Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys (GlobeNewswire)
May-29-24 07:56AM	Why Is Reshape Lifesciences (RSLS) Stock Up 80% Today? (InvestorPlace) +34.74%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-19-24 08:09AM	ReShape Lifesciences Inc. (NASDAQ:RSLS) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-16-24 03:07AM	Reshape Lifesciences Inc (RSLS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
08:54PM	Loading…
May-15-24 08:54PM	RSLS Stock Earnings: Reshape Lifesciences Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	ReShape Lifesciences Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-14-24 08:31AM	ReShape Lifesciences to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update (GlobeNewswire)
Apr-01-24 04:05PM	ReShape Lifesciences Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -11.82%
Mar-28-24 08:31AM	ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System (GlobeNewswire)
Mar-04-24 08:31AM	ReShape Lifesciences Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band 2.0 FLEX (GlobeNewswire) -5.75%
Feb-22-24 08:31AM	ReShape Lifesciences Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 FLEX (GlobeNewswire)
Jan-24-24 08:31AM	ReShape Lifesciences Conducts Bariatric Fellows Training for its Lap-Band System, Highlighting the Next-Generation Lap-Band 2.0 FLEX (GlobeNewswire) -5.18%
Dec-21-23 07:00AM	ReShape Lifesciences announces FDA PMA supplement approval for next-gen Lap-Band 2.0 Flex (News Direct)
Dec-20-23 08:31AM	ReShape Lifesciences Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives (GlobeNewswire)
Dec-13-23 09:49AM	Why Is ReShape Lifesciences (RSLS) Stock Up 68% Today? (InvestorPlace) +53.15%
Dec-12-23 04:05PM	ReShape Lifesciences Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band 2.0 FLEX (GlobeNewswire)
Nov-21-23 08:06AM	ReShape Lifesciences Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds (GlobeNewswire) -10.00%
Nov-12-23 12:52PM	ReShape Lifesciences Inc. (NASDAQ:RSLS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	ReShape Lifesciences Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan (GlobeNewswire) -9.18%
Nov-06-23 08:31AM	ReShape Lifesciences to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update (GlobeNewswire) -5.71%
Oct-25-23 08:14AM	Why Is Reshape Lifesciences (RSLS) Stock Up 59% Today? (InvestorPlace) +21.54%
Sep-29-23 12:30PM	ReShape Lifesciences Announces Pricing of $3.0 Million Public Offering (GlobeNewswire) -23.18%
Sep-22-23 08:31AM	ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI (GlobeNewswire)
Sep-21-23 08:31AM	ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System (GlobeNewswire) -9.33%
Sep-19-23 08:31AM	ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System (GlobeNewswire) -5.60%
Sep-14-23 08:31AM	ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device (GlobeNewswire)
Aug-07-23 04:05PM	ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -9.22%
Aug-03-23 04:05PM	ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update (GlobeNewswire)
Jun-29-23 08:31AM	ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software (GlobeNewswire)
Jun-28-23 08:31AM	ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation Device at the ASMBS 2023 Annual Meeting (GlobeNewswire) -6.62%
Jun-26-23 04:05PM	ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0 (GlobeNewswire) -13.71%
Jun-23-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -6.67%
Jun-20-23 10:58AM	Life Science Investor Forum Agenda Announced for June 22nd (GlobeNewswire)
Jun-14-23 08:31AM	ReShape Lifesciences® to Participate in Investor and Industry Conferences in June (GlobeNewswire)
May-15-23 04:05PM	ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-23 08:30AM	ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update (GlobeNewswire)
Apr-27-23 08:30AM	ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation Device at the Keystone Symposia on Type 2 Diabetes (GlobeNewswire)
Apr-25-23 04:05PM	ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -9.60%
Apr-20-23 08:30AM	ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market (GlobeNewswire) -8.04%
Apr-11-23 08:30AM	ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System (GlobeNewswire) +16.98%
Mar-28-23 09:50PM	ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call (GlobeNewswire) +12.03% -6.09%
Mar-23-23 08:30AM	ReShape Lifesciences Announces Formation of International Scientific Advisory Board (GlobeNewswire)
Mar-22-23 08:30AM	ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update (GlobeNewswire)
Mar-15-23 08:30AM	ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit (GlobeNewswire)
Feb-08-23 12:07PM	ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering (GlobeNewswire)
Feb-06-23 08:30AM	ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering (GlobeNewswire) -59.21%
Dec-22-22 08:30AM	ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022 (GlobeNewswire) +5.21%
Nov-14-22 07:30AM	ReShape Lifesciences Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-08-22 09:28AM	ReShape Lifesciences Announces $750,000 Registered Direct Offering (GlobeNewswire) -12.61%
Nov-07-22 01:22PM	ReShape Lifesciences to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update (GlobeNewswire) -6.00%
Nov-03-22 08:30AM	ReShape Lifesciences Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation Device at ObesityWeek® (GlobeNewswire)
Nov-02-22 09:11AM	ReShape Lifesciences to Present at the Q4 Investor Summit (GlobeNewswire)
Oct-31-22 08:30AM	ReShape Lifesciences Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band® (GlobeNewswire)
Oct-25-22 08:30AM	ReShape Lifesciences Announces Publication of Data on Proprietary Diabetes Bloc-Stim Neuromodulation (DBSN) System in Peer Reviewed, Frontiers in NeuroScience (GlobeNewswire) +5.26%
Oct-20-22 08:30AM	ReShape Lifesciences Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS) (GlobeNewswire)
Sep-22-22 08:30AM	ReShape Lifesciences Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device (GlobeNewswire)
Sep-14-22 08:30AM	ReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech Conference (GlobeNewswire)
Aug-23-22 08:30AM	ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations (GlobeNewswire) +5.06%
Aug-15-22 04:05PM	ReShape Lifesciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +5.49% -6.63%
Aug-10-22 04:30PM	ReShape Lifesciences to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update (GlobeNewswire) -8.16% +7.67%
12:05PM	ReShape Lifesciences Receives FDA 510(k) Clearance for the GIBI HD Calibration Tubes for use in Gastric and Bariatric Procedures (GlobeNewswire)
Jul-27-22 04:05PM	ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer (GlobeNewswire) -5.06% -5.35%
Jun-17-22 08:30AM	ReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross Proceeds (GlobeNewswire)
May-26-22 08:30AM	ReShape Lifesciences and OpenLoop Sign Agreement to Provide Nationwide Virtual Health Services for Weight Loss and Wellness Through reshapecare (GlobeNewswire) +11.25%
May-23-22 08:00AM	ReShape Lifesciences Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-19-22 08:30AM	ReShape Lifesciences Announces Vernon Vincent to be Recognized as the Distinguished Industry Partner at the ASMBS 2022 LEAD Gala and Awards (GlobeNewswire)
May-16-22 08:30AM	ReShape Lifesciences to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update (GlobeNewswire)
Apr-26-22 08:30AM	ReShape Lifesciences to Present at the Q2 Investor Summit (GlobeNewswire) -7.26%
Mar-31-22 11:33AM	Earnings Update: ReShape Lifesciences Inc. (NASDAQ:RSLS) Just Reported And Analysts Are Trimming Their Forecasts (Simply Wall St.) -12.59%
Mar-28-22 04:05PM	ReShape Lifesciences Reports Year Ended 2021 Financial and Operating Results and Provides Corporate Update (GlobeNewswire)
Mar-24-22 08:30AM	ReShape Lifesciences Experiences Continued Momentum of Direct-to-Consumer Marketing Campaign for the Lap-Band® (GlobeNewswire)
Mar-17-22 09:07AM	ReShape Lifesciences to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update (GlobeNewswire) +18.89%
Mar-09-22 08:30AM	ReShape Lifesciences to Participate in Investor Conferences in March (GlobeNewswire)
Jan-18-22 08:30AM	ReShape Lifesciences to Participate in the American Society for Metabolic and Bariatric Surgerys (ASMBS) Leadership Academy and re-UNITED Meeting January 19-22, 2022 in Las Vegas (GlobeNewswire)

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, the Obalon Balloon System, and the Diabetes Bloc-Stim Neuromodulation device. The firm sells the Lap-Band worldwide and is managed in the following geographical regions: United States, Australia, Europe, and the Rest of World. The company was founded in December 2002 and is headquartered in Irvine, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RSLS

ReShape Lifesciences Inc

Upgrade your FINVIZ experience